Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 5Breast Neoplasms 4Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Esophageal Neoplasms 2Stomach Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 36Magnetic Resonance Spectroscopy 23Gemcitabine 19Specimen Handling 15Nivolumab 12Carboplatin 12Surveys and Questionnaires 11Paclitaxel 11Cetuximab 11Early Intervention, Educational 10Bevacizumab 10Standard of Care 9Cyclophosphamide 9Cisplatin 9Radiosurgery 8Methods 8Fluorouracil 8Docetaxel 8Blood Specimen Collection 8Psychiatric Rehabilitation 7Pemetrexed 7sargramostim 6aldesleukin 6Taxes 6Injections 6Fluorodeoxyglucose F18 6Educational Status 6Drug Therapy 6Biopsy 6Albumin-Bound Paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × NVP-BKM120 × Gastrointestinal × Clear all
NCT01501604 2015-09-17

BKM120 in Cancers With PIK3CA Activating Mutations

Massachusetts General Hospital

Phase 2 Withdrawn
BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡